Despite promising clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant opposition from managed care entities. The organizations are https://aliviaojcy297706.blog5.net/94854452/the-drug-faces-is-dealing-with-pbm-hurdles-the-look-at-reimbursement-battles